We’re pleased to share that the full ARCHER clinical results will be presented by Dr. Leslie T. Cooper, Co-Chair of the ARCHER Steering Committee, at the ESC on Myocardial & Pericardial Diseases 2025 in Trieste, Italy (28–29 Nov). 🔗 Read the full press release:

Behind every breakthrough are brilliant minds united by purpose. CEO David Elsley shares timeless advice that continues to guide our mission today. Cardiol’s development programs bring together top global experts and regulatory partners to create safer, more effective therapies

🎥 Watch the full NASDAQ interview: https://t.co/tAESyUGC9i 📬 Join our Newsletter: https://t.co/qZteZYmiAP

Our recent topline ARCHER data demonstrated a reduction in heart size. As CEO David Elsley explains, this finding not only advances our myocarditis program but also highlights the broader potential in heart failure — a condition that is an order of magnitude greater in

We're proud to see Cardiol Therapeutics highlighted on the Nasdaq Tower after completing a US$11.4M financing — advancing our next-generation heart-disease therapies and pivotal clinical programs. $CRDL #CardiolRx #Biotech #HeartHealth #Nasdaq

"We are pleased to have secured a direct investment of US $11.4 million to strengthen our balance sheet and accelerate the development of our novel heart failure drug, CRD-38.” — David Elsley, President & CEO 🔗 Read the full Press Release: https://t.co/ao7VqYHZ8p CRD-38

Cardiol Therapeutics has secured US$11 million in new financing, extending our cash runway into Q3 2027. ⬇️Read the full Press Release⬇️ https://t.co/MbaXwXYErS “As recruitment in our pivotal Phase III MAVERIC trial gains momentum, with several prominent centers across the U.S.

"We had a significant impact on LV mass." - CEO, David Elsley, on our ARCHER trial in myocarditis. The ARCHER results will be submitted for presentation at an upcoming scientific meeting and for publication, supporting efforts to ensure the data are shared with the cardiology

ICI cancer medications save lives, but approximately 10,000 people annually may face a life-threatening side effect: ICI-associated myocarditis. #Myocarditis is the #1 cause of sudden cardiac death in people under 35. At @CardiolRx, we recognise innovative treatments must be

On #WorldHeartDay 2025, we unite against cardiovascular disease, the world's #1 killer. At @CardiolRx, we're advancing innovative therapies like CardiolRx™ and CRD-38 to combat heart inflammation and fibrosis. Let's protect every heart! #HeartHealth @worldheartfed

Not all heart measures carry the same weight. Left ventricular (LV) mass is more than a number – it has emerged as a critical factor in identifying cardiovascular risk. See why clinicians view it as a key measure in heart health:

Watch @CardiolRx President/CEO, David Elsley, and CMO/Head of R&D, Andrew Hamer, participated in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference in New York last week. ⬇️Watch the Fireside Chat now ⬇️ https://t.co/33H9lrFQvh

Join @PericarditisA on Oct 7, 2025 at 12:00pm EST to learn about #pericardial disease from national and international experts in the field, including members from our SC: Allan Klein, MD @ClevelandClinic, Massimo Imazio, MD, University Hospital Santa Maria della Misericordia, and

Cardiol Therapeutics (CRDL): Poised for Breakthrough in Cardiovascular Treatment - @CardiolRx *Sponsored

Watch @CardiolRx President/CEO, David Elsley, and CMO/Head of R&D, Andrew Hamer, participate in a Fireside Chat at the @CanaccordGenuity 45th Annual Growth Conference in Boston, MA. 🔽Watch the Fireside Chat webcast🔽 https://t.co/ZPnJvdwQN0

A live webcast of the Fireside Chat can be accessible through the following link: ( https://t.co/ZPnJvdwiXs). The replay will be available for 90 days following the conference.

We are pleased to announce that we will participate in a Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference in Boston, MA, on August 12, 2025, at 9:30 a.m. EDT. Please read the full press release ⬇️ https://t.co/0o3F2O2HWs

Today we announced the topline results from ARCHER, the Company’s Phase II clinical trial in patients with acute myocarditis. Please read the full press release ⬇️ https://t.co/vvo3kzFa0F

We are pleased to announce database lock for ARCHER, the Phase II multi-national, randomized, double-blind, placebo-controlled trial investigating its lead asset, CardiolRx™, on myocardial recovery in patients with acute myocarditis. Please read the full press release ⬇️

Today we announced the results from our Annual General Meeting of Shareholders held virtually via live audio webcast on May 28, 2025. Please read the full press release ⬇️ https://t.co/eSRT41sROj